MedTrace Logo

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2019-06-26

Study results available
· View outcomes & findings →

Summary

The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Herpes zoster vaccine GSK1437173A

2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)

BIOLOGICAL

Placebo

2 vaccinations at Months 0 and 2 with placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-12
Primary Completion
2010-07-02
Completion
2010-07-02

Countries

  • United States
  • Czechia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802464 on ClinicalTrials.gov